Literature DB >> 19851720

The immunogenicity of the liposome-associated outer membrane proteins (OMPs) of Moraxella catarrhalis.

Daria Augustyniak1, Józef Mleczko, Jan Gutowicz.   

Abstract

The outer membrane proteins (OMPs) are the most immunogenic and attractive of the Moraxella catarrhalis vaccine antigens that may induce the protective immune response. The aim of this study was to determine the effectiveness of two types of OMP-associated phosphatidylcholine (PC) liposomal formulations (OMPs-PC, PC-OMPs) and of Zwittergent-based proteomicelles (OMPs-Z) in potentiating an anti-OMP systemic immune response in mice. The immunogenicities of the above preparations were evaluated by assessing serum anti-OMP IgG and IgA reactivity in the post-immunized mouse antisera using ELISA and Western blotting. Additionally, the cross-reactivity of the most effective anti-OMP response was determined using heterologous sera from both humans and mice. Both the proteoliposomes and the proteomicelles showed high immunogenic properties and did not elicit any distinct quantitative differences in the antibody titer or qualitative differences in the pattern of the mouse antisera. The post-immunized mouse antisera predominantly recognized a approximately 60-kDa OMP of M. catarrhalis. That protein was also found to be a highly cross-reactive antigen interacting with a panel of pooled mouse antisera produced by immunization either with whole cells or the purified OMPs of heterologous M. catarrhalis strains. Furthermore, normal sera collected from healthy children were found to be preferentially reactive with the 60-kDa OMP. The serum-specific IgG, IgA and IgM were respectively detected via immunoblotting in 90%, 85% and 30% of heterologous human sera. This similar immunogenic effectiveness of both OMP-associated liposomal formulations could contribute to the practical use of such formulations in the future in human vaccination. Moreover, the highly cross-reactive 60-kDa OMP seems to be an important antigenic marker of M. catarrhalis, and, as it is responsible for the induction of an antibody-mediated and long-lasting immune response, studying it may partially aid us in understanding the relatively low degree of pathogenicity of the bacterium in immunocompetent individuals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19851720      PMCID: PMC6276019          DOI: 10.2478/s11658-009-0035-z

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  47 in total

1.  Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci.

Authors:  K A Jolley; L Appleby; J C Wright; M Christodoulides; J E Heckels
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  Effect of liposomal antigens on the priming and activation of the immune system by dendritic cells.

Authors:  Eliane Shahum; Hélène-Marie Thérien
Journal:  Int Immunopharmacol       Date:  2002-03       Impact factor: 4.932

Review 3.  Liposomes: from biophysics to the design of peptide vaccines.

Authors:  F Frézard
Journal:  Braz J Med Biol Res       Date:  1999-02       Impact factor: 2.590

Review 4.  Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens.

Authors:  C R Alving
Journal:  Biochim Biophys Acta       Date:  1992-12-11

5.  Incorporation of bacterial membrane proteins into liposomes: factors influencing protein reconstitution.

Authors:  M M Parmar; K Edwards; T D Madden
Journal:  Biochim Biophys Acta       Date:  1999-09-21

Review 6.  Moraxella catarrhalis: a review of an important human mucosal pathogen.

Authors:  R Karalus; A Campagnari
Journal:  Microbes Infect       Date:  2000-04       Impact factor: 2.700

7.  A reservoir of Moraxella catarrhalis in human pharyngeal lymphoid tissue.

Authors:  Nadja Heiniger; Violeta Spaniol; Rolf Troller; Mattheus Vischer; Christoph Aebi
Journal:  J Infect Dis       Date:  2007-08-30       Impact factor: 5.226

8.  Salivary antibodies directed against outer membrane proteins of Moraxella catarrhalis in healthy adults.

Authors:  Patricia Stutzmann Meier; Nadja Heiniger; Rolf Troller; Christoph Aebi
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Mechanisms of membrane protein insertion into liposomes during reconstitution procedures involving the use of detergents. 2. Incorporation of the light-driven proton pump bacteriorhodopsin.

Authors:  J L Rigaud; M T Paternostre; A Bluzat
Journal:  Biochemistry       Date:  1988-04-19       Impact factor: 3.162

10.  The Moraxella catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells.

Authors:  Melissa M Holm; Serena L Vanlerberg; Ian M Foley; Darren D Sledjeski; Eric R Lafontaine
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

View more
  4 in total

Review 1.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

Review 2.  Vaccine targets against Moraxella catarrhalis.

Authors:  Dabin Ren; Michael E Pichichero
Journal:  Expert Opin Ther Targets       Date:  2015-08-26       Impact factor: 6.902

3.  Virulence factors of Moraxella catarrhalis outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution.

Authors:  Daria Augustyniak; Rafał Seredyński; Siobhán McClean; Justyna Roszkowiak; Bartosz Roszniowski; Darren L Smith; Zuzanna Drulis-Kawa; Paweł Mackiewicz
Journal:  Sci Rep       Date:  2018-03-21       Impact factor: 4.379

4.  The strongest resistance of Staphylococcus aureus to erythromycin is caused by decreasing uptake of the antibiotic into the cells.

Authors:  Elżbieta Piątkowska; Jerzy Piątkowski; Anna Przondo-Mordarska
Journal:  Cell Mol Biol Lett       Date:  2012-09-20       Impact factor: 5.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.